Skip to main content

Search This Blog

Prostate Cancer

Posts

Tumor biomarkers for diagnosis, prognosis and targeted therapy | Signal Transduction and Targeted Therapy

Get link
Facebook
X
Pinterest
Email
Other Apps

- November 08, 2026

Invalid Access Key! Invalid Access Key!

Can frequent UTIs be a sign of bladder cancer?

Get link
Facebook
X
Pinterest
Email
Other Apps

- November 08, 2026

Invalid Access Key! Invalid Access Key!

Vibration plates: Are there health benefits?

Get link
Facebook
X
Pinterest
Email
Other Apps

- November 08, 2026

Invalid Access Key! Invalid Access Key!

PET scans: What are they and what to expect

Get link
Facebook
X
Pinterest
Email
Other Apps

- November 08, 2026

Invalid Access Key! Invalid Access Key!

Can frequent UTIs be a sign of bladder cancer?

Get link
Facebook
X
Pinterest
Email
Other Apps

- November 07, 2026

Invalid Access Key! Invalid Access Key!

Hepatitis C and liver cancer: What to know

Get link
Facebook
X
Pinterest
Email
Other Apps

- November 07, 2026

Invalid Access Key! Invalid Access Key!

Vibration plates: Are there health benefits?

Get link
Facebook
X
Pinterest
Email
Other Apps

- November 07, 2026

Invalid Access Key! Invalid Access Key!

Powered by Blogger

Theme images by billnoll

Popular Posts

Tumor biomarkers for diagnosis, prognosis and targeted therapy | Signal Transduction and Targeted Therapy

- December 24, 2024

warning signs of colon cancer :: Article Creator I'm A 34-year-old With Colon Cancer And I Don't Know How Long I Have Left - I Kick Myself For Ignoring Two Key Warning Signs By JONATHAN NEAL FOR MAILONLINE Published: 06:42 EST, 9 December 2024Updated: 16:55 EST, 11 December 2024 A 34-year-old man diagnosed with incurable colon cancer has revealed the key symptoms he dismissed — in a bid to help others avoid the same fate. Joe Faratzis first began suffering problems in 2019, including 'a dull, mild ache' in the lower right of his abdomen from time to time that 'was easy to ignore and forget about'. He visited his doctor who asked about his bowel habits and referred him for scans but, heartbreakingly, Mr Faratzis didn't go through with the tests, admitting: 'I assumed it was unnecessary.' Six months later he began noticing blood on the toilet paper when he went to the bathroom, but again claims he 'wasn...

Switching Immune Cells From “Protect” to “Attack” Mode To Treat Prostate Cancer - Technology Networks

- July 03, 2020

Drugs that can ‘reprogramme’ immune cells from protecting cancer to attacking it could be an effective new treatment for some men with advanced prostate cancer, a new study shows. Researchers found that immune cells called macrophages, already drawn into prostate cancer tumours to help promote growth, can be targeted and rewired to attack the disease. In studies of cancer cells and mice with prostate cancer a so-called CXCR2 inhibitor, which blocks a protein receptor on macrophages, inhibited tumour growth by switching them from helping the tumour to triggering anti-tumour immune responses instead. The drug, called AZD5069, is now being studied in a clinical trial led by researchers at The Institute of Cancer Research and our partner hospital The Royal Marsden NHS Foundation Trust, to test its effectiveness in men with advanced prostate cancer. The new research, published in the journal published in the journal Cell Reports , was carried out by a Eur...

Finding clarity in confusion about prostate cancer screening - AdVantageNEWS.com

- June 23, 2019

Dr. Andy Peterson, a family physician at OSF Medical Group in Kewanee, often sees men make an appointment with him after a heart attack or a cancer scare. Men are notoriously bad about getting regular check-ups, but that could be changing. The latest data from the Centers for Disease Control and Prevention show 64 percent of men said they’d seen a doctor in the past six months. June is Men’s Health Month, designed to raise awareness about the need to get regular preventative screenings and check-ups. One of the more challenging messages involves prostate cancer screening. Recommendations have changed several times in the past decade, including as recently as a year ago. Dr. Eminajulo (Emi) Adekoya, a urologist with OSF HealthCare Medical Group in Alton, says the U.S. Preventative Services Task Force latest recommendations suggest a PSA blood test can reduce the chance of death from prostate cancer in some men but it can also lead to false positives, overtreatment and serious side e...

After Beating Cancer Twice, Larry King, 87, Has Died– Legendary Talk Show Host Had Incredible Staying Power - SurvivorNet

- August 18, 2021

Larry King, Hospitalized With COVID-19, Is a Warrior Larry King Live talk show host Larry King, 87, is currently in the hospital fighting COVID-19; he reportedly left the ICU on Sunday. King survived lung cancer in 2017 and prostate cancer in 1999; he has also suffered a stroke and heart disease in the past. For people battling cancer during the COVID-19 pandemic, it's especially important to exercise safety precautions, due to some cancer treatments leading to an immunocompromised state. Legendary TV host and broadcast journalist, Larry King, 87, has spoken of his "indomitable spirit" which allowed him to overcome multiple health issues, including lung cancer in 2017; now, King has passed away from cancer after a battle with COVID. He had previously been treated at Cedars Sinai Medical Center in Los Angeles. And due to safety protocols, it's being reported by CNN that his three sons are not able to visit him in the hospital. Related: A Message on World Lung Cancer D...

Iowa News Anchor Showered With Support After Revealing Breast ...

- June 27, 2023

prostate screening :: Article Creator Prostate Cancer Screening And The Golden Rule Of Humanity Takeshi Takahashi, public health physician, former urological surgeon Health and Welfare Bureau, Kitakyushu city office, Jyonai 1-1, Kitakyushu 803-8501, Japan jazzy{at}kuhp.Kyoto-u.Ac.Jp The discussion around prostate cancer screening continues.1 I worked as a urologist for 30 years. When I was young, I hoped only to become an independent urologist and to gain as much surgical experience as possible. But as I approached the target age for prostate specific antigen (PSA) screening, and having heard the opinions of public health experts,23 I could no longer recommend PSA … Senior Living: How To Treat, Prevent Prostate Issues, Including Cancer By Dr. Jennifer Liu, Guest columnist Prostate health is an important issue in aging men. Major health complications can arise from prostate issues, including prostate cancer, decreased quality...

Trends in risk-group distribution and Pentafecta outcomes in patients treated with nerve-sparing, robot-assisted radical prostatectomy: a 10-year low-intermediate volume single-center experience. - UroToday

- April 27, 2020

To evaluate the trends in risk-group distribution and Pentafecta outcomes in patients treated with nerve-sparing (NS), robot-assisted radical prostatectomy (RARP) in a single low-intermediate volume prostate cancer (PCa) center over a 10-year period. We queried a prospectively maintained database for patients who underwent NS RARP between 2009 and 2018 in a low-intermediate volume PCa center. Risk-groups were defined according to the D'Amico classification. Pentafecta outcomes referred to the postsurgical presence of potency and continence, and the absence of biochemical recurrence (BCR), positive surgical margins (PSM), and perioperative complications. The Kruskall-Wallis test, the t test and the Mann-Whitney tests were used when appropriate. 603 patients underwent NS RARP and 484 patients were evaluated for Pentafecta outcomes. Median postsurgical follow-up was 28 months. Overall, 137 (22.7%), 376 (62.3%), and 90 (15%) patients were diagnosed in the low-, intermediate-, and hig...

Genotype linked to shorter survival in metastatic prostate cancer - Urology Times

- March 02, 2020

Inheriting the adrenal-permissive HSD3B1(1245C) genotype is associated with worse outcomes in low-volume metastatic prostate cancer and might someday help identify patients who could benefit from escalated therapy, according to a recent study. In essence, some patients are genetically predisposed to having their prostate cancers make their own potent androgens, such as testosterone or dihydrotestosterone (DHT), from non-testicular sources, according to study author Nima Sharifi, MD, of Cleveland Clinic Genitourinary Malignancies Research Center, Cleveland. “This comes from germline inheritance of an effectively ‘fast’ enzyme by the gene HSD3B1 that allows for prostate cancer to make these androgens. What this means clinically is that men with low-volume metastatic prostate cancer who inherit this fast form of HSD3B1 treated with medical or surgical castration progress more quickly and have shorter survival compared with men who do not inherit this fast enzyme,” Dr. Sharifi said. Re...

Signs that Chemo Is Working: How Effectiveness Is Measured and Defined

- December 20, 2023

endometrial cancer differential diagnosis :: Article Creator Endometrial Cancer The COMPASS Program offers transportation help to certain patients being treated for breast, ovarian, fallopian tube, primary peritoneal, uterine or endometrial, vulvar, vaginal, or cervical cancer at Huntsman Cancer Institute. We provide gas cards, money for Lyft ride shares, and a shuttle services. Learn if you qualify. About Uterine Cancer Content Treatment depends on the individual patient and their cancer but typically involves a combination of therapies, including: Surgery. Surgery removes the cancerous tissue, typically a hysterectomy (removal of the uterus) as well as removal of the ovaries and lymph nodes near the tumor to determine if the cancer has spread. This is the most common initial treatment for endometrial cancer. Radiation. Radiation treatment uses high-energy x-rays to kill microscopic cancer cells that may remain after surgery. Chemot...

Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study. - UroToday

- February 11, 2020

The objective was to investigate the proportion of men with metastatic prostate cancer in groups defined by T stage, Gleason Grade Group (GGG) and serum levels of prostate-specific antigen (PSA) and if PSA can be used to rule in metastatic prostate cancer when combined with T stage and GGG. We identified 102,076 men in Prostate Cancer data Base Sweden 4.0 who were diagnosed with prostate cancer in 2006-2016. Risk of metastases was assessed for PSA stratified on T stage and five-tiered GGG. For men who had not undergone bone imaging, we used multiple imputation to classify metastatic prostate cancer. Advanced T stage, high GGG and high PSA were related to bone metastases. For example: only 79/38 190 (0.2%) of men with T1-2 and GGG 1 had PSA above 500 ng/mL, and 29/79 (44%) of these men had metastases; whereas 1 154/7 018 (16%) of men with T3-4 and GGG 5 had PSA above 500 ng/ml and 1 088/1 154 (94%) of these men had metastases. However, no PSA cut-off could accurately identify the majori...

Tolmar Affirms Full Supply of Eligard® (Leuprolide Acetate) for Injectable Suspension for the Palliative Management of Advanced Prostate Cancer - PRNewswire

- August 10, 2020

BUFFALO GROVE, Ill. , Aug. 10, 2020 /PRNewswire/ -- Tolmar Pharmaceuticals, Inc., a specialty pharmaceutical company, today affirmed the full availability of ELIGARD® (leuprolide acetate) for injectable suspension in all doses for patients undergoing palliative treatment for advanced prostate cancer. The company confirmed the complete inventory of product supply and also announced a production increase in response to reports of a shortage in the United States for a different leuprolide acetate injection product used in the palliative treatment for advanced prostate cancer. Tolmar has a demonstrated record of providing consistent supply of ELIGARD in the U.S. and globally across approximately 89 countries, with no shortages to date. On July 24, 2020 and re-verified on August 3, 2020 , the U.S. Food and Drug Administration (FDA) listed the Lupron Depot, 3 months, 22.5 mg PDS Kit and 6 months, 45 mg PDS Kit as not available and on backorder in its database of Current and Resolved Drug...

Archive

November 202621
October 202632
September 202634
August 202650
July 202656
June 202644
May 202631
April 202658
March 2026111
February 202677

Show more Show less

Labels

"cancer prostata" - Google News
"metastatic prostate cancer" - Google News
"prostate cancer causes" - Google News
"prostate cancer survival rate" - Google News
"prostate cancer treatment options" - Google News
"prostate cancer treatment" - Google News
"prostate cancer" - Google News
"prostatectomy" - Google News
"symptoms of prostate cancer in men" - Google News
cancer+prostata - Google News

Google News
IFTTT
metastatic prostate cancer
metastatic+prostate+cancer - Google News
prostate cancer
prostate cancer causes
prostate cancer survival rate
prostate cancer treatment
prostate cancer treatment options
prostate+cancer - Google News
prostate+cancer+causes - Google News
prostate+cancer+survival+rate - Google News
prostate+cancer+treatment - Google News
prostate+cancer+treatment+options - Google News
prostatectomy
prostatectomy - Google News
symptoms of prostate cancer in men
symptoms+of+prostate+cancer+in+men - Google News

Show more Show less